Latest Ratios: P/E Ratio -0.0x · EV/EBITDA N/A · ROE N/A. (2021–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Market Cap | $61024 | $3M | — | — | — | — |
| Enterprise Value | $13M | $16M | — | — | — | — |
| P/E Ratio → | -0.00 | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — |
| P/B Ratio | — | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | — |
| ROA | -1046.2% | -1046.2% | -371.7% | -703.2% | -326.3% | -90.7% |
| ROIC | — | — | — | — | — | — |
| ROCE | — | — | — | — | — | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — |
| Net Debt / Equity | — | — | — | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — |
| Interest Coverage | -6.03 | -6.03 | -1.09 | -1.40 | -2.22 | -1.53 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Current Ratio | 0.17 | 0.17 | 0.00 | 0.01 | 0.00 | 0.04 |
| Quick Ratio | 0.17 | 0.17 | 0.00 | 0.01 | 0.00 | 0.04 |
| Cash Ratio | 0.08 | 0.08 | 0.00 | 0.00 | 0.00 | 0.04 |
| Asset Turnover | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | — | — | — | — |
| Shares Outstanding | — | $334770 | $25844 | $134134 | $322249 | $322249 |
Imminent liquidity and solvency
As reported in financial statements, Profusa's ROIC has consistently trended into negative territory, reaching -17.3% in 2024Q3, which underscores the firm's inability to generate returns on invested capital while it remains in a pre-commercial phase characterized by heavy clinical trial expenditures and negligible revenue generation.
The persistent decay in ROIC suggests that the company is currently destroying shareholder value rather than compounding it, as capital is deployed into long-term R&D without a clear path to near-term commercialization. Investors should monitor whether future clinical milestones can reverse this trend, though the current trajectory indicates a structural inability to achieve positive returns on capital under the existing cost structure.
According to recent SEC filings, the company's current ratio has collapsed to a precarious 0.02 as of 2026Q1, reflecting an extreme lack of liquid assets relative to short-term obligations that leaves the firm highly vulnerable to even minor disruptions in its ability to secure external financing.
This liquidity profile suggests that the company is operating with virtually no margin for error, as the current ratio indicates that cash and equivalents are insufficient to cover even a fraction of near-term liabilities. Such a position warrants significant concern regarding the firm's ability to maintain its ongoing clinical development programs without immediate and potentially dilutive capital infusions.
Based on the provided balance sheet data, the company's debt-to-equity profile has become increasingly distorted, with total debt rising to $12.5 million by 2026Q1 while the equity base has shifted into a deep deficit, signaling a highly distressed capital structure that limits future financing flexibility.
The reliance on debt to fund operations in the absence of revenue suggests that the company is leveraging its balance sheet to survive rather than to grow, which increases the risk of insolvency. This trend appears unsustainable and may force management to seek restructuring or highly dilutive equity offerings to address the mounting debt obligations.
Investors frequently misapply P/E and EV/EBITDA ratios to Profusa, which obscures the firm's true financial state because these metrics assume a level of operational maturity and revenue stability that simply does not exist for a pre-commercial medical device company currently burning through its remaining cash reserves.
Using traditional valuation multiples for a company with zero revenue and negative margins is fundamentally flawed, as it ignores the existential risk posed by the company's cash burn rate. Instead, analysts should focus on the cash-to-burn ratio and the progress of clinical milestones, as these are the only metrics that accurately reflect the company's viability and potential for future commercial success.
Includes 30+ ratios · 5 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying PFSA stock.
Profusa, Inc. Common Stock's current P/E ratio is -0.0x. This places it at the 50th percentile of its historical range.
Based on historical data, Profusa, Inc. Common Stock is trading at a P/E of -0.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.